Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease

Journal of Clinical Investigation

Volumn 100, Issue 11, 1997, Pages 2766-2776

  Hogaboam, Cory M ^a,b   Vallance, Bruce A ^a   Kumar, Ashesh ^a   Addison, Christina L ^a   Graham, Frank L ^a   Gauldie, Jack ^a   Collins, Stephen M ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adenovirus; Gene therapy; Inflammatory bowel disease; Interleukin 4; Nitric oxide

Indexed keywords

BETA GALACTOSIDASE; GAMMA INTERFERON; INTERLEUKIN 4; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SODIUM CHLORIDE; TRINITROBENZENESULFONIC ACID;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE TRANSFER; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VIRUS RECOMBINANT;

EID: 0031467628     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119823     Document Type: Article

References (60)

1. Ulmer, J.B., J.J. Donnelly, S.E. Parker, G.H. Rhodes, P.P. Felgner, V.J. Dwarki, S.H. Gromkowski, R.R. Deck, C.M. DeWitt, A. Friedman, et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1745-1749.
2. Missol, E., A. Sochanik, and S. Szala. 1995. Introduction of murine II-4 gene into B16(F10) melanoma tumors by direct gene transfer with DNA-liposome complexes. Cancer Lett. 97:189-193.
3. Aramaki, Y., F. Nitta, R. Matsuno, Y. Morimura, and S. Tsuchiya. 1996. Inhibitory effects of negatively charged liposomes on nitric oxide production from macrophages stimulated by LPS. Biochem. Biophys. Res. Commun. 220:1-6.
4. Kass-Eisler, A., K. Li, and L.A. Leinwald. 1996. Prospects for gene therapy with direct injection of polynucleotides. Ann. NY Acad. Sci. 232-240.
5. Graham, F.L., and L. Prevec. 1991. Manipulation of adenovirus vectors. In Methods in Molecular Biology. Gene Transfer and Expression Protocols. E.J. Murray and J.M. Walker, editors. Humana Press Inc., Clifton, NJ. 109-127.
6. Braciak, T.A., S.K. Mittal, F.L. Graham, C.D. Richards, and J. Gauldie. 1993. Construction of recombinant human type 5 adenoviruses expressing rodent IL-6 genes. An approach to investigate in vivo cytokine function. J. Immunol. 151:5145-5153.
7. Vallance, B.A., C.M. Hogaboam, C.L. Addison, J. Gauldie, and S.M. Collins. 1996. Interleukin-4 gene transfer to the intestine causes inflammation and muscle dysfunction in the mouse. Gastroenterology. 110:1034a. (Abstr.)
8. Xing, Z., T. Braciak, M. Jordana, K. Croitoru, F.L. Graham, and J. Gauldie. 1994. Adenovirus-mediated cytokine gene transfer at tissue sites. Overexpression of IL-6 induces lymphocytic hyperplasia in the lung. J. Immunol. 153: 4059-4069.
9. Addison, C.L., T. Braciak, R. Ralston, W.J. Muller, J. Gauldie, and F.L. Graham. 1995. Intratumoral injection of an adenovirus expressing interleukin-2 induces regression and immunity in a murine breast cancer model. Proc. Natl. Acad. Sci. USA. 92:8522-8526.
10. Cayeux, S., C. Beck, B. Dorken, and T. Blankenstein. 1996. Coexpression of interleukin-4 and B7.1 in murine tumour cells leads to improved tumour rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum. Gene Ther. 7:525-529.
11. Schneider, M.D., and B.A. French. 1993. The advent of adenovirus gene therapy for cardiovascular disease. Circulation. 88:1937-1942.
12. Kusugami, K., T. Matsuura, G.A. West, K.R. Youngman, D. Rachmilewitz, and C. Fiocchi. 1991. Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gatroenterology. 101:1594-1605.
13. Sadlack, B., H. Merz, H. Schorle, A. Schimpi, A.C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:253-261.
14. Kuhn, R., J. Lohler, D. Rennick, K. Rajewsky, and W. Muller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:263-274.
15. Mombaerts, P., E. Mizoguchi, M.J. Grusby, L.H. Glimcher, A.K. Bhan, and S. Tonegawa. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 75:275-282.
16. Mizoguchi, A., E. Mizoguchi, C. Chiba, G.M. Spiekermann, S. Tonegawa, C. Nagler-Anderson, and A.K. Bhan. 1996. Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J. Exp. Med. 183:847-856.
17. Powrie, F., R. Correa-Oliveira, S. Mauze, and R.L. Coffman. 1994. Regulatory interactions between CD45RBhigh and CD45RBlow CD4 T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179:589-600.
18. + T cells. Am. J. Pathol. 148:1503-1515.
19. Choi, P.M., and S.R. Targan. 1994. Immunomodulator therapy in inflammatory bowel disease. Dig. Dis. Sci. 39:1885-1892.
20. Schreiber, S., T. Heinig, U. Panzer, R. Reinking, A. Bouchard, P.D. Stahl, and A. Raedler. 1995. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology. 108:21-33.
21. Schreiber, S., T. Heinig, H.-G. Thiele, and A. Raedler. 1995. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology. 108:1434-1444.
22. Van Dulleman, H.M., S.J.H. Van Deventer, D.W. Hommes, H.S. Bijl, G.N.J. Jansen, G.N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 109:129-135.
23. Bauditz, J., Y. Ruckert, A. Raedler, S. Nikolaus, H. Lochs, and S. Schrieber. 1995. Tumor necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet. 345:1445.
24. Derkx, B., J. Taminiau, S. Radema, A. Stronkhorst, C. Wortel, G. Tytgat, and S. Van Deventer. 1993. Tumor necrosis factor antibody in Crohn's disease. Lancet. 342:173-174.
25. Morris, G.P., P.L. Beck, M.S. Herridge, W.T. Depew, M.R. Szewczuk, and J.L. Wallace. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 96:795-803.
26. Wallace, J.L. 1994. Novel targets for anti-inflammatory therapy in IBD. In Inflammatory Bowel Disease. Basic Research, Clinical Implications and Trends in Therapy. L.R. Sutherland, S.M. Collins, F. Martin, R.S. McLeod, S.R. Targan, J.L. Wallace, and C.N. Williams, editors. Kluwer Academic Publishers, London. 374-382.
27. West, G.A., T. Matsuura, A.D. Levine, J.S. Klein, and C. Fiocchi. 1996. Interleukin-4 in inflammatory bowel disease and mucosal immune reactivity. Gastroenterology. 110:1683-1695.
28. Cohen, M.C., and S. Cohen. 1996. Cytokine function: a study in biologic diversity. Am. J. Clin. Pathol. 105:589-598.
29. Gautam, S.C., N.F. Chikkala, and T.A. Hamilton. 1992. Anti-inflammatory action of IL-4. Negative regulation of contact sensitivity to trinitrochlorobenzene. J. Immunol. 148:1411-1415.
30. Snyder, S.H. 1993. Pharmacology: janus faces of nitric oxide. Nature. 364:577-587.
31. Boughton-Smith, N.K. 1994. Pathological and therapeutic implications for nitric oxide in inflammatory bowel disease. J. R. Soc. Med. 87:312-314.
32. Hogaboam, C.M., K. Jacobson, S.M. Collins, and M.G. Blennerhassett. 1995. The selective beneficial effects of nitric oxide inhibition in experimental colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 268:G673-G684.
33. Miller, M.J.S., H. Sadowska-Krowicka, S. Chotinaruemol, J.L. Kakkis, and D.A. Clark. 1993. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J. Pharmacol. Exp. Ther. 264:11-16.
34. Miller, M.J.S., and D.A. Clark. 1994. Nitric oxide synthase inhibition can initiate or prevent gut inflammation: role of enzyme source. Agents Actions. 41(Suppl. C PT 2):C231-C232.
35. Rachmilewitz, D., F. Karmeli, E. Okon, and M. Bursztyn. 1995. Experimental colitis is ameliorated hy inhibition of nitric oxide synthase activity. Gut. 37:247-255.
36. Miller, M.J.S., J.H. Thompson, X.-J. Zhang, H. Sadowska-Krowicka, J.L. Kakkis, U.K. Munshi, M. Sandoval, J.L. Rossi, S. Eloby-Childress, J.S. Beckman, et al. 1995. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology. 109:1475-1483.
37. Neurath, M.F., I. Fuss, B.L. Kelsall, E. Stuber, and W. Strober. 1995. Antibodies to interleukin-12 abrogate established experimental colitis in mice. J. Exp. Med. 182:1281-1290.
38. Elson, C.O., R.B. Sartor, G.S. Tennyson, and R.H. Riddell. 1995. Experimental models of inflammatory bowel disease. Gastroenterology. 109:1344-1367.
39. Huard, J., G. Lochmuller, G. Acsadi, A. Jani, B. Massie, and G. Karpati. 1995. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther. 2:107-115.
40. Khan, I., and S.M. Collins. 1994. Expression of cytokines in the longitudinal muscle myenteric plexus of the inflamed intestine of rat. Gastroenterology. 107:691-700.
41. Sands, W.A., V. Bulut, A. Severn, D. Xu, and F.Y. Liew. 1994. Inhibition of nitric oxide synthesis by interleukin-4 may involve inhibiting the activation of protein kinase C epsilon. Eur. J. Immunol. 24:2345-2350.
42. Karges, W.J.P., R. Gaedigk, and H.-M. Dosch. 1994. Quantitative analysis of gene expression in different tissues by template-calibrated RT-PCR and laser-induced fluorescence. PCR Methods and Applications. 4:154-159.
43. Lowry, O.H., N.J. Rosebrough, A.L. Farr, and R.J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
44. Forough, R., D. Hasenstab, N. Koyama, H. Lea, M. Clowes, and A.W. Clowes. 1996. Generating antibodies against secreted proteins using vascular smooth muscle cells transduced with replication-defective retrovirus. BioTechniques. 20:694-696.
45. Juillard, V., P. Villefroy, D. Godfrin, A. Pavirani, A. Venet, and J.-G. Guillet. 1996. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. Eur. J. Pharmacol. 25:3467-3473.
46. Morga, E., and P. Heuschling. 1996. Interleukin-4 down regulates MHC II antigens on cultured rat astrocytes. Glia. 17:175-179.
47. Fiorentino, D.F., M.W. Bond, and T.R. Mosmann. 1989. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J. Exp. Med. 170:2081-2085.
48. Strober, W., and R.O. Ehrhardt. 1993. Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell. 75: 203-205.
49. Herfath, H., R. Janardham, H.C. Rath, and R.B. Sartor. 1996. In vivo IL-10 treatment suppresses experimental chronic granulomatous inflammation and has an additive effect with coritcosteroids. Gastroenterology. 110:855a. (Abstr.)
50. Ribbons, K.A., S. Eloby-Childress, J. Thompson, X.J. Zhang, K. Pennline, and M.J.S. Miller. 1996. Effect of interleukin-10 in TNBS-induced colitis in rats. Gastroenterology. 110:856a. (Abstr.)
51. Grisham, M.B., R.D. Specian, and T.E. Zimmerman. 1994. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J. Pharmacol. Exp. Ther. 271:1114-1121.
52. Quere, S., V. Bertrand, M. Tulliez, L. Chauvelot-Moachon, J. Charreirre, and M. Breban. 1996. The effects of IL-10 treatment on the inflammatory bowel disease in transgenic rats expressing HLA-B27 and human β microglobulin. Gastroenterology. 110:763a. (Abstr.)
53. Aiko, S., and M.B. Grisham. 1995. Spontaneous intestinal inflammation and nitric oxide metabolism in HLA-B27 transgenic rats. Gastroenterology. 109:142-150.
54. Alican, I., and P. Kubes. 1996. A critical role for nitric oxide in intestinal barrier function and dysfunction. Am. J. Physiol. Gastrointest. Liver Physiol. 270:G225-G237.
55. Miller, M.J.S., and M.B. Grisham. 1995. Nitric oxide as a mediator of inflammation? You had better believe it. Mediat. of Inflamm. 4:387-396.
56. Mourelle, M., F. Casellas, F. Guarner, A. Salas, V. Riveros-Moreno, S. Moncada, and J.-R. Malagelada. 1995. Induction of nitric oxide synthase in colonic smooth muscle from patients with toxic megacolon. Gastroenterology. 109:1497-1502.
57. Moncada, S. 1993. The L-arginine: nitric oxide pathway, cellular transduction and immunological roles. Adv. Second Messenger Phosphoprotein Res. 28:97-99.
58. Kusugami, K., A. Fukatsu, M. Tanimoto, M. Shinoda, J.-I. Haruta, A. Kuroiwa, K. Ina, K. Kanayama, T. Ando, T. Matsuura, T. Yamaguchi, K. Morise, M. Ieda, H. Iokawa, A. Ishihara, and S. Sarai. 1995. Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent. Dig. Dis. Sci. 40:949-959.
59. Kolios, G., D.A.F. Robertson, and J. Westwick. 1996. Interleukin-13 regulates the nitric oxide production in human colonic epithelial cells. Comparison with interleukin-4 and interleukin-10. Gastroenterology. 110:822a. (Abstr.)
60. Kucharzik, T., N. Lugering, H. Weigelt, M. Adolf, W. Domschke, and R. Stoll. 1996. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10. Clin. Exp. Immunol. 104:483-490.